Clinical study on simultaneously modified pulmonary vein isolation and left atrial ablation during off-pump coronary artery bypass grafting
10.3760/cma.j.cn112434-20240131-00030
- VernacularTitle:心脏不停搏冠状动脉旁路移植同期改良肺静脉隔离左心房消融治疗冠心病合并房颤的近期效果分析
- Author:
Hui LI
1
;
Changcheng LIU
;
Haiyang LI
Author Information
1. 首都医科大学附属北京安贞医院心脏外科，北京 100029
- Keywords:
Atrial fibrillation;
Coronary heart disease;
Atrial radiofrequency ablation;
Coronary artery bypass grafting
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2024;40(5):284-287
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To innovatively applicate and evaluate the efficacy of simultaneous off-pump coronary artery bypass grafting (OPCABG), modified pulmonary vein isolation and left atrial ablation treating coronary heart disease combined with atrial fibrillation.Methods:From January 2021 to August 2023, a retrospective analysis was conducted on the clinical data of 76 patients who underwent OPCABG, modified pulmonary vein isolation and left atrial ablation in our department. There were 57 males and 19 females, aged(63.42 ± 8.25)years, with a median duration of 26 months of atrial fibrillation. Follow up was conducted for 1 year after surgery, and 24-hour dynamic electrocardiogram was rechecked to observe the recurrence of atrial fibrillation.Results:All patients successfully completed the surgery without any conversion to extracorporeal circulation, and no perioperative death. On the first day after surgery, there was a conversion to sinus or junctional rhythm in 69(90.79%) cases. The median postoperative hospitalization time was 7 days, with no postoperative cerebral infarction or complications of thoracotomy hemostasis. All patients recovered and were discharged, with a sinus rhythm maintained at 67(88.16%) upon discharge. Compared with preoperation, there were 56 (73.68%) patients with sinus rhythm after 1 year of postoperative follow-up( P<0.05). Conclusion:The simultaneous OPCABG, modified pulmonary vein isolation and left atrial ablation treating coronary heart disease with atrial fibrillation was safe, feasible, and effective. The mid- and long-term efficacy needs to be further confirmed through multicenter and large-scale studies.
